Abstract

Recent efforts have attempted to convert non-blood cells into hematopoietic stem cells (HSCs) with the goal of generating blood lineages de novo. Here we show that hematopoietic transcription factors Scl, Lmo2, Runx1 and Bmi1 can convert a developmentally distant lineage (fibroblasts) into ‘induced hematopoietic progenitors' (iHPs). Functionally, iHPs generate acetylcholinesterase+ megakaryocytes and phagocytic myeloid cells in vitro and can also engraft immunodeficient mice, generating myeloerythoid and B-lymphoid cells for up to 4 months in vivo. Molecularly, iHPs transcriptionally resemble native Kit+ hematopoietic progenitors. Mechanistically, reprogramming factor Lmo2 implements a hematopoietic programme in fibroblasts by rapidly binding to and upregulating the Hhex and Gfi1 genes within days. Moreover the reprogramming transcription factors also require extracellular BMP and MEK signalling to cooperatively effectuate reprogramming. Thus, the transcription factors that orchestrate embryonic hematopoiesis can artificially reconstitute this programme in developmentally distant fibroblasts, converting them into engraftable blood progenitors.

Highlights

  • Recent efforts have attempted to convert non-blood cells into hematopoietic stem cells (HSCs) with the goal of generating blood lineages de novo

  • We started with a pool of seven well-characterized factors (‘7F’), namely Scl (S), Lmo[2] (L), Runx[1] (R), HoxB4 (H), Bmi[1] (B), Gfi[1] (G1) and Gata[2] (G2)[26,27] in p53 À / À mouse embryonic fibroblasts (MEFs), given indications that p53 À / À MEFs are more reprogrammed into iPSCs28 or blood progenitors[24]

  • Here we show that the combined action of four transcription factors (Scl, Lmo[2], Runx[1] and Bmi1) can decisively redirect the fate of mouse fibroblasts, reprogramming them into engraftable hematopoietic progenitors

Read more

Summary

Introduction

Recent efforts have attempted to convert non-blood cells into hematopoietic stem cells (HSCs) with the goal of generating blood lineages de novo. Scl is one of the earliest-acting regulators of HSC specification and is critical for hemogenic endothelium specification, and Lmo[2] normally acts as a bridge cofactor to Scl, whereas separately, core-binding factor Runx[1] participates in a distinct transcriptional complex[11,12,13,14,15,16]. After their developmental specification, foetal and neonatal HSC self-renew due to the action of Sox[17] The implementation and perpetuation of the HSC programme is directed by an ordered series of transcription factors during both embryogenesis and adulthood

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call